302 related articles for article (PubMed ID: 17264951)
1. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
5. [The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia].
Martínez Velasco E; Gómez Castillo JJ; Fernández Megía MJ; González Joga B; Barreda Hernández D; Gómez Roncero MI
Farm Hosp; 2007; 31(2):124-7. PubMed ID: 17590122
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
Chemnitz JM; Uener J; Hallek M; Scheid C
Ann Hematol; 2010 Oct; 89(10):1029-33. PubMed ID: 20422413
[TBL] [Abstract][Full Text] [Related]
8. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
[TBL] [Abstract][Full Text] [Related]
10. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
11. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura.
Patino W; Sarode R
J Clin Apher; 2007 Feb; 22(1):17-20. PubMed ID: 17285618
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.
Valent P; Lechner K
Wien Klin Wochenschr; 2008; 120(5-6):136-51. PubMed ID: 18365153
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura.
Albaramki JH; Teo J; Alexander SI
Pediatr Nephrol; 2009 Sep; 24(9):1749-52. PubMed ID: 19399522
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.
Rubia J; Moscardó F; Gómez MJ; Guardia R; Rodríguez P; Sebrango A; Zamora C; Debén G; Goterris R; López R; Peña F; Pujol M; Vidaller A; Río-Garma JD; Sanz MA;
Transfus Apher Sci; 2010 Dec; 43(3):299-303. PubMed ID: 20934383
[TBL] [Abstract][Full Text] [Related]
17. Maintenence rituximab following induction in autoimmune cytopenias.
Rai MP; Lee EJ; Bussel JB
Br J Haematol; 2023 Jul; 202(1):153-158. PubMed ID: 37086173
[TBL] [Abstract][Full Text] [Related]
18. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.
Aleem A
Ann Saudi Med; 2008; 28(5):382-5. PubMed ID: 18779631
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]